The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.

The FDA blinks, giving Huntington’s patients hope—and uniQure shareholders a windfall.

The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in…